Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
about
Economic considerations in the management of Alzheimer's diseaseCholinesterase inhibitors for Alzheimer's diseaseLong-term course and effectiveness of combination therapy in Alzheimer diseaseThe use of herbal medicine in Alzheimer's disease-a systematic reviewPersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsAssessment and management of behavioral and psychological symptoms of dementiaEvidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's DiseaseThe serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's diseaseCholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's diseaseThe timing of drug funding announcements relative to elections: a case study involving dementia medicationsSubmitted for your consideration: potential advantages of a novel clinical trial design and initial patient reactionCost-effectiveness of drug therapies for Alzheimer's disease: A brief review.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice.The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Upper gastrointestinal bleed associated with cholinesterase inhibitor useCholinesterase inhibitors: drugs looking for a disease?Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures.Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezilDementia care initiative in primary practice: study protocol of a cluster randomized trial on dementia management in a general practice setting.Should older adults be screened for dementia? It is important to screen for evidence of dementia!Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial.Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting.Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based studyInformal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Change ObservedLong-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.Update on the pharmacological treatment of Alzheimer's diseaseDiscontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer diseaseCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.Progress in Alzheimer's disease.Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies.Current and emerging drug treatment options for Alzheimer's disease: a systematic review.
P2860
Q22241448-F7537E3F-2457-4BF7-977E-6A1CBDF3969BQ22252975-AE35801A-9373-4DF0-9908-AE0C35493CA6Q24642161-BB1A34DD-9353-431E-B455-69E24C3744E4Q24673334-A1792247-C0AE-480F-AFAB-03410117E398Q26997299-54EDE9A0-77DC-40E6-86E1-F468E28CF546Q28088782-8D3F2567-97E8-4278-8039-A0310C031D1DQ28212725-FEBDF860-52EB-4205-801B-742A7DBE1A66Q28251394-BB8FD731-1F4C-4934-9ADD-9676A4B3045EQ28287090-0D5C71C7-CCE6-489A-B5DB-8C5B3B9A1DABQ28287100-9A7AC0E2-770D-4A0F-8C0F-FC0755AF0A9FQ28486951-6DC96461-B5BB-45CC-8A13-5DF305DD3534Q28728556-CA6EE6E5-D5C0-4669-9249-1F255D18D8EAQ30441091-87DC5ED7-ED3E-400A-9674-C3B7ED482947Q30443975-5D557262-318B-4875-A0B2-32C731698284Q30477103-E0C2831D-02BF-4DB0-A413-829D2CF80174Q30831806-110E330B-324E-493F-A959-82EF715722B7Q30833736-075F5382-92BF-4077-9F16-E75C656B2954Q33165693-30677D8B-2D1D-4D60-81DE-E935DC843DF5Q33165801-B1629007-FA65-4FAE-AE15-1044D4BAA29AQ33166305-05878EA9-0B07-4AD9-9BA3-3F46C3DF54FDQ33238993-105135B8-8182-4BCB-8261-D475C35DD321Q33289262-A6DBF56F-4E40-447B-A099-841EEB7F28ADQ33305144-CB4EF3CB-540F-4E2F-8560-12204813266DQ33408028-82C16BE6-A857-4638-95D9-4FA061601AD6Q33461875-DBF5FA26-0377-4170-9371-3B9F4A6BAC3BQ33584316-ED802680-7125-47CD-B538-50015BE2DB73Q33589655-18A6E882-0C05-417C-9437-BA4D172298D7Q33596862-E62F4924-79C6-4EE4-A15F-20364CC097C7Q33662471-95D7C86A-0C5A-4FD7-885F-329636A8762BQ33718205-7C753F65-955E-4FAF-B525-1EE117973E24Q33736183-21B55513-DC03-46A9-98F1-65E9BE6BEB18Q33790288-4A8AF18A-6426-4A8F-A545-3EBBFABF95FAQ33836947-3BDCDD28-9CC7-4E14-A966-7A94051CF60CQ33858264-3257EF05-0319-4E34-96DC-C882ED1526B5Q33867858-08F32A77-2179-4DE1-B1EA-FCFBC6ECECDAQ33912750-DFC6FABC-7703-4869-B7BB-076220F8CD3DQ33928316-9E1C4859-698F-4B79-9AE3-E0880CC52317Q33943357-1FE14058-9394-4846-B05C-D038B04028C4Q34156798-15CD8856-7870-4872-AA3D-D851F4226DEBQ34222721-2531683F-BC66-4822-8C0A-862FDBC43EA9
P2860
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Long-term donepezil treatment ...... randomised double-blind trial.
@ast
Long-term donepezil treatment ...... randomised double-blind trial.
@en
type
label
Long-term donepezil treatment ...... randomised double-blind trial.
@ast
Long-term donepezil treatment ...... randomised double-blind trial.
@en
prefLabel
Long-term donepezil treatment ...... randomised double-blind trial.
@ast
Long-term donepezil treatment ...... randomised double-blind trial.
@en
P2093
P1433
P1476
Long-term donepezil treatment ...... randomised double-blind trial
@en
P2093
AD2000 Collaborative Group
C Courtney
E Sellwood
P304
P356
10.1016/S0140-6736(04)16499-4
P407
P577
2004-06-01T00:00:00Z